Rise Advisors’s BioLife Solutions BLFS Stock Holding History

Rise Advisors’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-40	Closed	-$914	–	1556
2025 Q1	$914	Buy	+40	New	+$1.05K	﹤0.01%	1286

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Rise Advisors's BLFS Position: Q2 2025 in Review

Rise Advisors sold out of BioLife Solutions (BLFS) in Q2 2025, closing a stake of 40 shares — an estimated $914 sold.

Rise Advisors first reported a position in BLFS in Q1 2025 and held it in 1 quarter. The position peaked at $914 in Q1 2025. 194 funds tracked by Wall St. Rank hold BLFS as of Q2 2025.

Rise Advisors reported no remaining BioLife Solutions position as of Q2 2025 after selling out during the quarter.
Rise Advisors sold 40 BioLife Solutions shares in Q2 2025, an estimated $914.
Rise Advisors first reported a position in BioLife Solutions in Q1 2025 and held it in 1 quarter.
Rise Advisors's BioLife Solutions position peaked at $914 in Q1 2025.
194 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.